Leiden University Medical Center Invests in Denator AB's Novel Technology to Stabilize Tissue Samples for Proteomic Analysis

Gothenburg, Sweden, and Leiden, The Netherlands - 24.06. 2008.

Denator AB announced today that the Department of Parasitology / Biomolecular Mass Spectrometry Unit, at the Center for Infectious Diseases in the Leiden University Medical School, has invested in the company’s novel tissue stabilization technology.

Professor André Deelder, Head of Department, explained the reasoning behind the decision: “In common with many researchers, particularly those in the proteomics field, we are concerned that protein degradation upstream can interfere significantly with downstream results. Degradation effects may occur very rapidly after sampling and, with conventionally treated snap-frozen samples, the risk of further degradation returns when samples need to be thawed. Preliminary results indicate that Denator’s rapid heat inactivation technology stabilizes tissues instantly and this stability is maintained during downstream analyses. We are very optimistic that this new approach will bring us closer to the original biological state of the samples, facilitating data interpretation and opening the way to discover novel proteins and peptides that would previously have been lost.”

Olof Sköld, CEO at Denator, stated: “We are extremely pleased that Professor Deelder’s laboratory has taken this decision. We have recently set up several research collaborations to test our novel technology platform and obtain valuable user feedback during the critical product development stage. So far, results are very positive and we are confident that we are on the path to successful commercialization of Denator technology.”

Denator’s first commercial system for instant tissue stabilization will be launched at the HUPO meeting in Amsterdam in August, 2008.

About Denator

Denator intends to become the leading supplier of products that stabilize biological tissues and fluids at the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company’s proprietary heat-inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden. For more information visit: www.denator.com or contact:

Charlotte Emlind
Business Development
Denator AB
E-mail: charlotte.emlind@denator.com
Tel.: +46 31 41 28 91
Fax.: +46 41 28 40

Back to news